HK1201452A1 - Methods of reducing risk of cardiovascular disease - Google Patents
Methods of reducing risk of cardiovascular disease Download PDFInfo
- Publication number
- HK1201452A1 HK1201452A1 HK15101958.1A HK15101958A HK1201452A1 HK 1201452 A1 HK1201452 A1 HK 1201452A1 HK 15101958 A HK15101958 A HK 15101958A HK 1201452 A1 HK1201452 A1 HK 1201452A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- patient
- ldl
- compound
- formula
- risk
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261584002P | 2012-01-06 | 2012-01-06 | |
| US61/584,002 | 2012-01-06 | ||
| PCT/US2013/020317 WO2013103842A1 (en) | 2012-01-06 | 2013-01-04 | Methods of reducing risk of cardiovascular disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK19131240.4A Addition HK40007806A (en) | 2012-01-06 | 2015-02-27 | Methods of reducing risk of cardiovascular disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1201452A1 true HK1201452A1 (en) | 2015-09-04 |
Family
ID=48745439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15101958.1A HK1201452A1 (en) | 2012-01-06 | 2013-01-04 | Methods of reducing risk of cardiovascular disease |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10028926B2 (enExample) |
| EP (2) | EP3735967A1 (enExample) |
| JP (2) | JP6295205B2 (enExample) |
| CN (2) | CN110025608A (enExample) |
| AU (1) | AU2013207423B2 (enExample) |
| CA (1) | CA2861643C (enExample) |
| HK (1) | HK1201452A1 (enExample) |
| MX (1) | MX367352B (enExample) |
| WO (1) | WO2013103842A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DK4108671T3 (da) | 2010-10-01 | 2025-01-06 | Modernatx Inc | Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| JP6113737B2 (ja) | 2011-10-03 | 2017-04-12 | モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． | 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法 |
| KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| US9440754B2 (en) | 2012-03-29 | 2016-09-13 | R.P. Scherer Technologies, Llc | Three circuit fill system for blow fill seal containers |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| EP2834259A4 (en) | 2012-04-02 | 2016-08-24 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| BR112015026513A2 (pt) | 2013-04-17 | 2017-07-25 | Pfizer | derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| AU2015346037A1 (en) | 2014-11-14 | 2017-07-06 | Gemphire Therapeutics Inc. | Processes and intermediates for preparing alpha,omega-dicarboxylic acid-terminated dialkane ethers |
| WO2016149191A1 (en) | 2015-03-13 | 2016-09-22 | Esperion Therapeutics, Inc. | Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
| MA41793A (fr) * | 2015-03-16 | 2018-01-23 | Esperion Therapeutics Inc | Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire |
| RU2018120599A (ru) * | 2015-11-06 | 2019-12-09 | Джемфир Терапьютикс, Инк. | Лечение смешанной дислипидемии |
| AU2017224230A1 (en) * | 2016-02-26 | 2018-08-30 | Gemphire Therapeutics Inc. | Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapy |
| US20210361618A1 (en) * | 2017-02-08 | 2021-11-25 | Esperion Therapeutics, Inc. | Triplet combination formulations and methods for treating or reducing the risk of cardiovascular disease |
| IL269884B2 (en) | 2017-04-18 | 2023-09-01 | Gemphire Therapeutics Inc | Gamkaban its accepted pharmaceutical salts, their compositions and methods of their use |
| US20190008779A1 (en) * | 2017-05-11 | 2019-01-10 | Gemphire Therapeutics Inc. | Gemcabene compositions and methods of use thereof |
| CN109666727B (zh) * | 2018-12-29 | 2020-11-06 | 中国药科大学 | 一种高活性抑制pcsk9表达的微小rna的用途 |
| RS66416B1 (sr) | 2019-01-18 | 2025-02-28 | Astrazeneca Ab | 6'-[[(1s,3s)-3-[[5-(difluorometoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i metode njegove primene |
| US12344578B2 (en) | 2019-06-21 | 2025-07-01 | Esperion Therapeutics, Inc. | Salt forms of bempedoic acid and methods for using the same |
| CN113134086B (zh) * | 2020-01-20 | 2024-05-24 | 深圳市长卿医学研究院 | 一种降血脂的药物组合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5648387A (en) | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
| NZ503982A (en) | 1997-12-12 | 2002-03-28 | Warner Lambert Co | Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus |
| US6861555B2 (en) | 2000-01-25 | 2005-03-01 | Warner-Lambert Company | Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith |
| US20020103252A1 (en) | 1997-12-12 | 2002-08-01 | Bisgaier Charles Larry | Statin-carboxyalkylether combinations |
| MXPA01009893A (es) | 1999-04-01 | 2003-07-28 | Esperion Therapeutics Inc | Compuestos con eter, composiciones y usos de estos. |
| MXPA03003021A (es) | 2000-10-11 | 2003-07-14 | Esperion Therapeutics Inc | Compuestos de eter y composiciones para el control del colesterol y usos relacionados. |
| US6645170B2 (en) | 2001-03-05 | 2003-11-11 | Bioject Medical Technologies, Inc. | Simplified disposable needle-free injection apparatus and method |
| US20040229954A1 (en) | 2003-05-16 | 2004-11-18 | Macdougall Diane Elaine | Selective manipulation of triglyceride, HDL and LDL parameters with 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt |
| US7345190B2 (en) | 2003-11-12 | 2008-03-18 | Ssv Therapeutics, Inc. | Carnitine conjugates as dual prodrugs and uses thereof |
| US7579504B2 (en) | 2005-12-07 | 2009-08-25 | Gilead Sciences, Inc. | ABCA1 elevating compounds |
| CN101522623B (zh) * | 2006-08-03 | 2013-06-12 | 塔夫茨大学信托人 | 无潮红烟酸类似物和其使用方法 |
-
2013
- 2013-01-04 CN CN201910123564.7A patent/CN110025608A/zh active Pending
- 2013-01-04 EP EP20166700.3A patent/EP3735967A1/en not_active Withdrawn
- 2013-01-04 MX MX2014008180A patent/MX367352B/es active IP Right Grant
- 2013-01-04 CA CA2861643A patent/CA2861643C/en active Active
- 2013-01-04 JP JP2014551345A patent/JP6295205B2/ja active Active
- 2013-01-04 US US14/370,722 patent/US10028926B2/en not_active Expired - Fee Related
- 2013-01-04 AU AU2013207423A patent/AU2013207423B2/en not_active Ceased
- 2013-01-04 EP EP13733913.1A patent/EP2800564B1/en active Active
- 2013-01-04 CN CN201380004642.2A patent/CN104136023A/zh active Pending
- 2013-01-04 HK HK15101958.1A patent/HK1201452A1/xx unknown
- 2013-01-04 WO PCT/US2013/020317 patent/WO2013103842A1/en not_active Ceased
-
2018
- 2018-02-19 JP JP2018026939A patent/JP2018104452A/ja active Pending
- 2018-06-29 US US16/024,288 patent/US10709678B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110025608A (zh) | 2019-07-19 |
| AU2013207423A1 (en) | 2014-07-24 |
| US20150005386A1 (en) | 2015-01-01 |
| EP2800564A1 (en) | 2014-11-12 |
| EP2800564A4 (en) | 2015-07-22 |
| US10709678B2 (en) | 2020-07-14 |
| US20180303779A1 (en) | 2018-10-25 |
| WO2013103842A1 (en) | 2013-07-11 |
| CA2861643A1 (en) | 2013-07-11 |
| EP3735967A1 (en) | 2020-11-11 |
| US10028926B2 (en) | 2018-07-24 |
| CA2861643C (en) | 2020-10-06 |
| CN104136023A (zh) | 2014-11-05 |
| AU2013207423B2 (en) | 2017-10-12 |
| MX367352B (es) | 2019-08-16 |
| JP2018104452A (ja) | 2018-07-05 |
| JP2015503588A (ja) | 2015-02-02 |
| EP2800564B1 (en) | 2020-05-06 |
| JP6295205B2 (ja) | 2018-03-14 |
| MX2014008180A (es) | 2014-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10709678B2 (en) | Methods of reducing risk of cardiovascular disease | |
| US11744816B2 (en) | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease | |
| Nikolic et al. | ETC-1002: a future option for lipid disorders? | |
| WO2013136277A1 (en) | Pharmaceutical compositions for treatment of cardiovascular diseases | |
| KR20100106958A (ko) | 신장 보호제로서 중쇄 길이 지방산 및 글리세라이드 | |
| WO2019178023A1 (en) | Methods of Treating or Preventing Acute Respiratory Distress Syndrome | |
| JP2009540003A (ja) | Ａａ１ｒａの低頻度投与を含む腎機能の長期間にわたる改善 | |
| HK1250484A1 (zh) | 用於治疗胰腺炎的吉卡宾和衍生物 | |
| HK40007806A (en) | Methods of reducing risk of cardiovascular disease | |
| AU2015202580B2 (en) | Gemcabene and derivatives for treating pancreatitis | |
| CN102416015A (zh) | 一种含他汀类药物的组合物及其用途 | |
| HK1238159A1 (en) | Gemcaben for treating pancreatitis | |
| HK1192147A (en) | Gemcabene and derivatives for treating pancreatitis | |
| MXPA05003599A (en) | Simvastatin combinations for improving the lipid profile and reducing risk factors of cardiovascular diseases in patients with dyslipidemic disorders | |
| JP2013032400A (ja) | ＨＭＧ−ＣｏＡリダクターゼ阻害剤、トコフェロール類及びＣｏＱ１０を含有する医薬組成物２ |